Immuneering (IMRX) Income from Continuing Operations (2020 - 2023)
Historic Income from Continuing Operations for Immuneering (IMRX) over the last 4 years, with Q4 2023 value amounting to -$15.5 million.
- Immuneering's Income from Continuing Operations fell 1543.57% to -$15.5 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$54.8 million, marking a year-over-year decrease of 803.36%. This contributed to the annual value of -$54.8 million for FY2023, which is 849.74% down from last year.
- As of Q4 2023, Immuneering's Income from Continuing Operations stood at -$15.5 million, which was down 1543.57% from -$13.1 million recorded in Q3 2023.
- In the past 5 years, Immuneering's Income from Continuing Operations ranged from a high of -$3.6 million in Q2 2020 and a low of -$15.5 million during Q4 2023
- Over the past 4 years, Immuneering's median Income from Continuing Operations value was -$11.5 million (recorded in 2022), while the average stood at -$10.2 million.
- Per our database at Business Quant, Immuneering's Income from Continuing Operations tumbled by 12162.34% in 2021 and then tumbled by 81.48% in 2023.
- Quarter analysis of 4 years shows Immuneering's Income from Continuing Operations stood at -$5.8 million in 2020, then crashed by 88.02% to -$11.0 million in 2021, then decreased by 22.75% to -$13.5 million in 2022, then dropped by 15.44% to -$15.5 million in 2023.
- Its Income from Continuing Operations stands at -$15.5 million for Q4 2023, versus -$13.1 million for Q3 2023 and -$12.3 million for Q2 2023.